<?xml version="1.0" encoding="UTF-8"?>
<ref id="b0100">
 <label>20</label>
 <element-citation publication-type="journal" id="h0100">
  <person-group person-group-type="author">
   <name>
    <surname>Hoffmann</surname>
    <given-names>M.</given-names>
   </name>
   <name>
    <surname>Schroeder</surname>
    <given-names>S.</given-names>
   </name>
   <name>
    <surname>Kleine-Weber</surname>
    <given-names>H.</given-names>
   </name>
   <name>
    <surname>Müller</surname>
    <given-names>M.A.</given-names>
   </name>
   <name>
    <surname>Drosten</surname>
    <given-names>C.</given-names>
   </name>
   <name>
    <surname>Pöhlmann</surname>
    <given-names>S.</given-names>
   </name>
  </person-group>
  <article-title>Nafamostat mesylate blocks acrivation of SARS-CoV-2: new treatment option for COVID-19</article-title>
  <source>Antimicrob. Agents Chemother.</source>
  <volume>64</volume>
  <year>2020</year>
  <fpage>e00754</fpage>
  <lpage>e820</lpage>
  <pub-id pub-id-type="doi">10.1128/AAC.00754-20</pub-id>
  <pub-id pub-id-type="pmid">32312781</pub-id>
 </element-citation>
</ref>
